mercredi 26 octobre 2016

Onco Actu du 26 octobre 2016

1. Biologie

Solving the Lack of Diversity in Genomic Research [MIT Technology Review]

2.10 Etiologie - Alcool

Women now drinking 'almost as much alcohol as men' [NHS Choices]

2.6 Etiologie - Environnement

Exclusive: WHO cancer agency asked experts to withhold weedkiller documents [Reuters]

3.1 Tabac

ASCO Concerned by Continued Toll Taken by Cigarette Use Taking in the U.S., Particularly Among Southern States [ASCO]

3.1.1 Tabac - e-cigs

E-cigarettes could be used to help combat obesity in smokers trying to quit: study [Reuters]

4.5 Dép., diag. & prono. - Colorectal

There’s an Easier Way to Screen for Colon Cancer [Time]

5. Traitements

New UK research illuminates new developments for anticancer treatment [Pharmafile]

Researchers deploy viruses to improve cancer treatments [Cancer Research UK]

5.10 Traitements - Essais

OncoGenex Announces Positive Survival Results from Apatorsen Phase 2 Borealis-2™ Trial in Metastatic Bladder Cancer [OncoGenex]

5.12 Immunothérapies

New Results Presented for Opdivo (nivolumab) Demonstrate Encouraging Response Rate in an Expanded Population of Heavily Pre-Treated Classical Hodgkin Lymphoma Patients [BMS]

Tetra-punch against solid tumors [NIHilist's Immunology Blog]

5.2 Pharma

AZ’ Lynparza delays ovarian cancer progression, data show [PharmaTimes]

Readying for pricing fight, drug lobby to add $100 million to coffers [STAT]

Drug lobby adds $100M to war chest ahead of pricing battle [Politico]

5.2.3 Pharma - économie

Merck Revenue and Profit Rise on Cancer Drugs, Vaccines [Wall Street Journal]

5.3 Traitements - FDA, EMA, NICE...

The FDA’s Controversial Duchenne Drug Approval And The Moral Impulse To Rescue [Health Affairs Blog]

6.1 Observation

Let's be honest: the NHS is costing thousands of lives [The Telegraph]

6.10.1 Politiques (USA)

ASCO Recommends Key Priorities for 21st Century Cures [ASCO]

6.5 Médecines alternatives

Regrets of a Naturopath [In the Pipeline]